Basil Golding

Company: U.S. FDA

Job title: Director, Office of Plasma Protein Therapeutics in CBER

Seminars:

9:30 am Harnessing the Use of NK Cells with Fc Factor 8: Precision Targeting of Unwanted B-Cells Producing Factor 8 Antibodies 9:30 am

Uncovering the potential of Fc Factor 8 to activate NK cells with precision for specific targeting Addressing autoimmune disorders characterized by antibodies against self-antigens The therapeutic potential of activating NK cells to eliminate autoimmune B-cells while minimizing collateral damageRead more

day: Conference Day One